These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27696441)

  • 1. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.
    Mafirakureva N; Mapako T; Khoza S; Emmanuel JC; Marowa L; Mvere D; Postma MJ; van Hulst M
    Transfusion; 2016 Dec; 56(12):3101-3111. PubMed ID: 27696441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.
    Davidson T; Ekermo B; Gaines H; Lesko B; Åkerlind B
    Transfusion; 2011 Feb; 51(2):421-9. PubMed ID: 20849409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.
    Marshall DA; Kleinman SH; Wong JB; AuBuchon JP; Grima DT; Kulin NA; Weinstein MC
    Vox Sang; 2004 Jan; 86(1):28-40. PubMed ID: 14984557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan.
    Moiz B; Moatter T; Shaikh U; Adil S; Ali N; Mahar F; Shamsuddin N; Khurshid M
    Transfusion; 2014 Jun; 54(6):1652-9. PubMed ID: 24383918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
    Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
    Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?
    Stramer SL; Notari EP; Krysztof DE; Dodd RY
    Transfusion; 2013 Oct; 53(10 Pt 2):2449-58. PubMed ID: 23607261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.
    Cable R; Lelie N; Bird A
    Vox Sang; 2013 Feb; 104(2):93-9. PubMed ID: 22924987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations.
    Jackson BR; Busch MP; Stramer SL; AuBuchon JP
    Transfusion; 2003 Jun; 43(6):721-9. PubMed ID: 12757522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; de Wit GA; Bonsel GJ; van Hout BA
    Transfusion; 2009 Feb; 49(2):311-9. PubMed ID: 19389213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?
    Stramer SL; Zou S; Notari EP; Foster GA; Krysztof DE; Musavi F; Dodd RY
    Transfusion; 2012 Feb; 52(2):440-6. PubMed ID: 21810101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis.
    Lai JC; Kahn JG; Tavakol M; Peters MG; Roberts JP
    Am J Transplant; 2013 Oct; 13(10):2611-8. PubMed ID: 24034208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
    Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of triplex nucleic acid test assays in United States blood donors.
    Stramer SL; Krysztof DE; Brodsky JP; Fickett TA; Reynolds B; Dodd RY; Kleinman SH
    Transfusion; 2013 Oct; 53(10 Pt 2):2525-37. PubMed ID: 23550838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.